 "Lupin hits fresh 52-week low; down 7.5% in six days")
Lupin hit a fresh 52-week low of Rs 1,320, down 1.3% in intra-day trade, extending its 6.4% decline in past five trading sessions on the BSE.
According to news reports, US health regulator issued Form 483 with three observations to Lupin Goa plant. The US Food and Drug Administration inspected this plant between March 27 and April 7, 2017.
According to news reports, US health regulator issued Form 483 with three observations to Lupin Goa plant. The US Food and Drug Administration inspected this plant between March 27 and April 7, 2017.
CLICK HERE FOR MINT REPORT
CLICK HERE FOR MONEY CONTROL REPORT
The observations, as per reports, are- failure to review any unexplained discrepancy; no written procedures for production and process controls; control procedures that monitor output of manufacturing processes not established.
“Goa plant of the company contributed close to 50% of the US sales (around 25% of consolidated revenue) and accounted for 30 outstanding ANDAs and thus very important for Lupin growth plans. While it’s difficult to assess the impact on the same as the company still has time to respond back to the queries and also, since queries are small and can be responded,” said Sarabjit Kour Nangra, VP Research- Pharma, Angel Broking.
As of now we are not changing the estimates and maintain our BUY rating with a price target of Rs 1809, the brokerage said in client note.
At 10:38 am; the stock was down less than 1% at Rs 1,325 on BSE against 0.32% decline in the S&P BSE Sensex. A combined 723,845 equity shares changed hands on the counter on BSE and NSE so far.
CLICK HERE FOR MONEY CONTROL REPORT
The observations, as per reports, are- failure to review any unexplained discrepancy; no written procedures for production and process controls; control procedures that monitor output of manufacturing processes not established.
“Goa plant of the company contributed close to 50% of the US sales (around 25% of consolidated revenue) and accounted for 30 outstanding ANDAs and thus very important for Lupin growth plans. While it’s difficult to assess the impact on the same as the company still has time to respond back to the queries and also, since queries are small and can be responded,” said Sarabjit Kour Nangra, VP Research- Pharma, Angel Broking.
As of now we are not changing the estimates and maintain our BUY rating with a price target of Rs 1809, the brokerage said in client note.
At 10:38 am; the stock was down less than 1% at Rs 1,325 on BSE against 0.32% decline in the S&P BSE Sensex. A combined 723,845 equity shares changed hands on the counter on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%